Racura Oncology (RAC) AGM 2024 summary

Opening remarks and agenda

• Executive Chair welcomed shareholders and introduced the board and management team, highlighting significant progress in FY24 and outlining the meeting's structure, including a Q&A session with stakeholders.

Financial performance review

• Cash at bank stood at $14.62m as of 30 September 2024, with no debt and a market capitalisation of $251.88m.

• $5m was raised via a bonus option issue in June 2024, with potential for an additional $25m from piggyback options by May 2026.

Board and executive committee updates

• Board renewal included the retirement of Mary Harney and Phil Lynch, with Dr Pete Smith appointed Executive Chair and Dr Serge Scrofani joining as Non-Executive Director.

• Dr Daniel Tillett transitioned to Managing Director/CEO, reflecting his expanded leadership role.

• Strengthened Scientific and Clinical Advisory Boards with key appointments, including Associate Professor Erin Howden and Professor Daniel Von Hoff.